The use of antiinflammatory therapy and macrolides in bronchiectasis.
Airway inflammation is a major component of disease pathogenesis in bronchiectasis, suggesting that antiinflammatory therapies could be of benefit in treatment. This article addresses the use of anti-inflammatory/immunomodulatory therapies in the management of patients with bronchiectasis and individually discusses the use of corticosteroids, macrolides, and other potential anti-inflammatory agents.
Division of Pulmonology, Department of Internal Medicine, Faculty of Health Sciences, Charlotte Maxeke Johannesburg Academic Hospital, University of the Witwatersrand, South Africa. charles.feldman@wits.ac.za
Charles
C
Feldman
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use*; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D001987:Bronchiectasis / Q000188:drug therapy*; D006801:Humans; D018942:Macrolides / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
D000305:Adrenal Cortex Hormones; D000893:Anti-Inflammatory Agents; D018942:Macrolides